Get AI intraday signals

GET DAILY SIGNALS

Doximity (DOCS) Plunges: Unveiling the Reasons Behind Its -10.93% Monthly Descent

DOCS sees its Stochastic Oscillator recovers from oversold territory

On September 14, 2026, the Stochastic Oscillator for DOCS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 61 instances where the indicator left the oversold zone. In 46 of the 61 cases the stock moved higher in the following days. This puts the odds of a move higher at over 75%.

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +6.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where DOCS advanced for three days, in 211 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The 10-day RSI Indicator for DOCS moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DOCS as a result. In 56 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for DOCS turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. DOCS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.023) is normal, around the industry mean (7.455). P/E Ratio (30.726) is within average values for comparable stocks, (45.054). Projected Growth (PEG Ratio) (0.590) is also within normal values, averaging (1.518). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (7.740) is also within normal values, averaging (6.089).

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.